Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
FDA approves second generic mifepristone, boosting access for early abortion up to 10 weeks.
The FDA approved a second generic version of the abortion pill mifepristone, made by Evita Solutions, for use up to 10 weeks of pregnancy.
The drug, which blocks progesterone to end early pregnancies, is 97% effective when combined with misoprostol.
The approval, finalized in September 2025, follows standard regulatory review and aims to increase access and affordability.
It has drawn immediate criticism from anti-abortion groups and Republican leaders, who called the decision dangerous and urged a safety review.
The FDA maintains the drug is safe and effective, despite ongoing political pressure and legal challenges over its distribution.
La FDA aprueba el segundo mifepristone genérico, aumentando el acceso para el aborto temprano hasta 10 semanas.